GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - BEAM THERAPEUTICS INC

Explicit Guidance:

• Ristocella (Sickle Cell) BLA Submission: Targeting the submission of the first Biologics License Application (BLA) for Ristocella by the end of the current year.
• Ristocella Commercial Launch: Expecting to launch Ristocella in 2027, subject to FDA review priority.
• BEAM-302 (Alpha-1 Antitrypsin Deficiency): Anticipating completion of the pivotal trial in the first half of 2026.
• Pipeline Expansion: Projecting the launch of at least four programs by the end of the decade, including BEAM-301 (GSD Ia), BEAM-302, Ristocella, and the new BEAM-303 (PKU) program.
• Pricing/Cost Logic: Noting that while initial pricing is expected to be higher than chronic therapies, the elimination of lifelong treatment (projected at ~$10M lifetime cost for competitors) will result in an overall net reduction in healthcare costs, a concept aligned with current administration and FDA policy.

Business-Segment Outlook:

• Ristocella (Ex Vivo): Demonstrated a differentiated clinical profile achieving the highest reported Hemoglobin F levels and reducing Hemoglobin S to <40%; manufacturing process is fully automated with high reliability (median mobilization steps: 1, vs. 2+ for competitors), addressing previous industry challenges with uptake.
• BEAM-302 (In Vivo/AAT): In pivotal phase with FDA agreement on an accelerated approval path based on biomarkers (total AAT levels ≥11 micromolar) rather than new clinical endpoints; data suggests restoration to an MZ phenotype, effectively eliminating disease progression risk.
• BEAM-301 (In Vivo/GSD Ia): Moving toward the optimal biological dose (60 mcg) after observing transformative clinical effects (15-hour fasting window vs. 2-hour prior) at 40 mcg; planning redosing of initial cohort at optimal dose upon identification.
• BEAM-303 (In Vivo/PKU): Established a "single IND" strategy with the FDA for a basket trial covering multiple mutations (approx. 50% of patient population); planning to enter clinical phase with the most prevalent mutation (R48W) to establish dose, then advancing to other mutations without repeating titration, potentially requiring only in vitro data for very rare mutations later.
• Technology Platform: Leveraging the LNP-mRNA platform for cross-referencing data across programs to avoid redundant GLP toxicity studies; expanding target tissues beyond the liver to other tissues in the future.

Market and Competitive Outlook:

• Competitive Positioning: Claiming the most advanced position for Alpha-1 Antitrypsin Deficiency, currently offering a curative approach vs. competitor enzyme replacement therapies which only slow progression; positioning Ristocella as having a superior safety profile (no double-stranded breaks) and more reliable manufacturing compared to existing ex vivo products (Casgevy, Lyfgenia).
• Market Shift: Anticipating a systemic shift by the FDA and healthcare system from chronic dosing models to "once-and-done" therapies to reduce long-term costs.
• Pricing Dynamics: Operating under the assumption that payers and the administration will recognize the net cost benefit of one-off cures despite high upfront pricing, similar to the market reception of Casgevy and Lyfgenia.

Macro / Industry Outlook:

• Regulatory Environment: Benefiting from recent FDA draft guidance on basket trials, which allows for efficient mutation-based coverage and reduced clinical trial burdens for rare diseases; FDA recognized the feasibility of accelerated approval based on established biomarkers.
• IP Landscape: Secured broad Cas9 rights via a licensing deal with Editas; maintaining that the company is productive and protected from ongoing Berkeley/Broad litigation, though the ultimate resolution will be monitored.
• Clinical Trial Design: Utilizing new regulatory flexibility to accelerate development timelines, particularly for ultra-rare diseases where small patient populations allow for approval on limited data points.

Strategic Initiatives:

• Ristocella Launch: Preparing for commercial launch in 2027 following BLA submission by year-end.
• Pivotal Trial Advancement: Accelerating BEAM-302 pivotal data readout to early 2026.
• PKU Program Initiation: Planning imminent clinical entry for PKU using a multi-mutation basket trial design to cover 50% of the population efficiently.
• Dose Optimization: Commitment to redosing patients in BEAM-301 with the optimal biological dose once established.
• Geographic/Therapeutic Expansion: Developing a pipeline that includes liver-targeted therapies beyond the current scope and exploring non-liver tissue targets.

Risks and Headwinds to Outlook:

• FDA Review Timing: Ristocella launch timeline depends on whether the FDA grants priority review status.
• Variable Patient Response: In BEAM-301, one patient (compound heterozygote with BMI of 53) showed lower response; uncertainty exists on whether high BMI or genetic complexity caused the reduced efficacy.
• Litigation Resolution: Ongoing disputes regarding Cas9 IP between academic institutions (Berkeley/Broad) could impact future rights, though current position is secure.
• Trial Completion: BEAM-302 pivotal completion is targeted for H1 2026; any delays could impact the accelerated approval timeline.
• Manufacturing Reliability: While optimized, the reliance on automated mobilization and cell collection remains a critical operational success factor for ex vivo programs.

Management Tone on the Future:

• High Confidence: Describes Ristocella efficacy as "extremely pleased" and "transformative," with claims of the "highest level of hemoglobin F" reported to date.
• Aggressive Timeline: Management expresses strong conviction in the 2027 launch window and the ability to have four programs launched by the end of the decade.
• Strategic Clarity: Tone is confident regarding the "once-and-done" value proposition and the regulatory pathway's alignment with their technology.
• Hedges: Cautious regarding the specific timing of Ristocella launch pending FDA priority review status; acknowledges the need to resolve the individual non-response case in BEAM-301 before finalizing dosing protocols for the broader population.

Miscellaneous:

• Cell Dose Specifics: Ristocella dose is 3.5 million cells per kg; doses lower than this link to engraftment failure.
• Manufacturing Efficiency: Median mobilization steps for Ristocella patients were 1, significantly lower than the industry standard of 2+, attributed to the gentler nature of the base editing process requiring fewer cells.
• Safety Profile: Fastest neutrophil engraftment times observed, reducing risks of opportunistic infections and hospitalization duration.